{ "instance": { "bivi-20230630_10k.htm": { "axisCustom": 0, "axisStandard": 17, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 654, "http://xbrl.sec.gov/dei/2023": 37 }, "contextCount": 200, "dts": { "calculationLink": { "local": [ "bivi-20230630_cal.xml" ] }, "definitionLink": { "local": [ "bivi-20230630_def.xml" ] }, "inline": { "local": [ "bivi-20230630_10k.htm" ] }, "labelLink": { "local": [ "bivi-20230630_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20230630_pre.xml" ] }, "schema": { "local": [ "bivi-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 504, "entityCount": 1, "hidden": { "http://bioviepharma.com/20230630": 39, "http://fasb.org/us-gaap/2023": 101, "http://xbrl.sec.gov/dei/2023": 3, "total": 143 }, "keyCustom": 80, "keyStandard": 243, "memberCustom": 42, "memberStandard": 18, "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioviepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Investments in U.S. Treasury Bills available for sale", "menuCat": "Notes", "order": "10", "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSale", "shortName": "Investments in U.S. Treasury Bills available for sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "11", "role": "http://bioviepharma.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "12", "role": "http://bioviepharma.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Other Liabilities", "menuCat": "Notes", "order": "13", "role": "http://bioviepharma.com/role/OtherLiabilities", "shortName": "Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Notes Payable", "menuCat": "Notes", "order": "14", "role": "http://bioviepharma.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "15", "role": "http://bioviepharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Equity Transactions", "menuCat": "Notes", "order": "16", "role": "http://bioviepharma.com/role/EquityTransactions", "shortName": "Equity Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Leases", "menuCat": "Notes", "order": "17", "role": "http://bioviepharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "18", "role": "http://bioviepharma.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:EmployeeBenefitPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Employee Benefit Plan", "menuCat": "Notes", "order": "19", "role": "http://bioviepharma.com/role/EmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:EmployeeBenefitPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://bioviepharma.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://bioviepharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "21", "role": "http://bioviepharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "22", "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "23", "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Investments in U.S. Treasury Bills available for sale (Tables)", "menuCat": "Tables", "order": "24", "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleTables", "shortName": "Investments in U.S. Treasury Bills available for sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "25", "role": "http://bioviepharma.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Notes Payable (Tables)", "menuCat": "Tables", "order": "26", "role": "http://bioviepharma.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "27", "role": "http://bioviepharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Equity Transactions (Tables)", "menuCat": "Tables", "order": "28", "role": "http://bioviepharma.com/role/EquityTransactionsTables", "shortName": "Equity Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "29", "role": "http://bioviepharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bivi:UnearnedPremiumAnddiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://bioviepharma.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bivi:UnearnedPremiumAnddiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "30", "role": "http://bioviepharma.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bivi:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Liquidity and Going Concern (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative", "shortName": "Liquidity and Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bivi:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Significant Accounting Policies (Details)", "menuCat": "Details", "order": "32", "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Investments in U.S. Treasury Bills available for sale (Details)", "menuCat": "Details", "order": "34", "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "shortName": "Investments in U.S. Treasury Bills available for sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock", "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember", "decimals": "0", "lang": null, "name": "bivi:AmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-012023-06-30_us-gaap_USTreasuryBillSecuritiesMember", "decimals": "0", "first": true, "lang": null, "name": "bivi:NumberOfStockPurchased", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Investments in U.S. Treasury Bills available for sale (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative", "shortName": "Investments in U.S. Treasury Bills available for sale (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-012023-06-30_us-gaap_USTreasuryBillSecuritiesMember", "decimals": "0", "first": true, "lang": null, "name": "bivi:NumberOfStockPurchased", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Intangible Assets (Details)", "menuCat": "Details", "order": "36", "role": "http://bioviepharma.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Intangible Assets (Details 1)", "menuCat": "Details", "order": "37", "role": "http://bioviepharma.com/role/IntangibleAssetsDetails1", "shortName": "Intangible Assets (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Intangible Assets (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative", "shortName": "Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2022-08-15_custom_AcuitasGroupHoldingsLLCMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://bioviepharma.com/role/StatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Other Liabilities (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://bioviepharma.com/role/OtherLiabilitiesDetailsNarrative", "shortName": "Other Liabilities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bivi:NotesPayableNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Notes Payable (Details)", "menuCat": "Details", "order": "41", "role": "http://bioviepharma.com/role/NotesPayableDetails", "shortName": "Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bivi:NotesPayableNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:ScheduleofFutureAmortizationExpenseTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30_custom_UnearnedDiscountMember", "decimals": "0", "first": true, "lang": null, "name": "bivi:AmortizationExpenseNextRollingTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Notes Payable (Details 1)", "menuCat": "Details", "order": "42", "role": "http://bioviepharma.com/role/NotesPayableDetails1", "shortName": "Notes Payable (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:ScheduleofFutureAmortizationExpenseTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30_custom_UnearnedDiscountMember", "decimals": "0", "first": true, "lang": null, "name": "bivi:AmortizationExpenseNextRollingTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Notes Payable (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://bioviepharma.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Fair Value Measurements (Details)", "menuCat": "Details", "order": "44", "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Fair Value Measurements (Details 1)", "menuCat": "Details", "order": "45", "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "shortName": "Fair Value Measurements (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2021-07-012022-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Fair Value Measurements (Details 2)", "menuCat": "Details", "order": "46", "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "shortName": "Fair Value Measurements (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Fair Value Measurements (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative", "shortName": "Fair Value Measurements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2021-11-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Equity Transactions (Details)", "menuCat": "Details", "order": "48", "role": "http://bioviepharma.com/role/EquityTransactionsDetails", "shortName": "Equity Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2021-06-30_custom_StockOptionsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Equity Transactions (Details 1)", "menuCat": "Details", "order": "49", "role": "http://bioviepharma.com/role/EquityTransactionsDetails1", "shortName": "Equity Transactions (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2021-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity", "shortName": "Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2021-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Equity Transactions (Details 2)", "menuCat": "Details", "order": "50", "role": "http://bioviepharma.com/role/EquityTransactionsDetails2", "shortName": "Equity Transactions (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30_custom_StockOption1Member", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Equity Transactions (Details 3)", "menuCat": "Details", "order": "51", "role": "http://bioviepharma.com/role/EquityTransactionsDetails3", "shortName": "Equity Transactions (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember325698968", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2022-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Equity Transactions (Details 4)", "menuCat": "Details", "order": "52", "role": "http://bioviepharma.com/role/EquityTransactionsDetails4", "shortName": "Equity Transactions (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2021-06-30_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Equity Transactions (Details Narrative)", "menuCat": "Details", "order": "53", "role": "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "shortName": "Equity Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "54", "role": "http://bioviepharma.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Leases (Details 1)", "menuCat": "Details", "order": "55", "role": "http://bioviepharma.com/role/LeasesDetails1", "shortName": "Leases (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Leases (Details 2)", "menuCat": "Details", "order": "56", "role": "http://bioviepharma.com/role/LeasesDetails2", "shortName": "Leases (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Leases (Details Narrative)", "menuCat": "Details", "order": "57", "role": "http://bioviepharma.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "bivi:EmployeeBenefitPlanTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Employee Benefit Plan (Details Narrative)", "menuCat": "Details", "order": "58", "role": "http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative", "shortName": "Employee Benefit Plan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "bivi:EmployeeBenefitPlanTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "59", "role": "http://bioviepharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://bioviepharma.com/role/StatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "0", "lang": null, "name": "bivi:StockBasedCompensationRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Income Taxes (Details 1)", "menuCat": "Details", "order": "60", "role": "http://bioviepharma.com/role/IncomeTaxesDetails1", "shortName": "Income Taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "61", "role": "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-012023-06-30_custom_SalesAgreementMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "62", "role": "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2023-07-012023-08-15_us-gaap_SubsequentEventMember_custom_SalesAgreementMember_custom_AgentMember", "decimals": "INF", "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Background Information", "menuCat": "Notes", "order": "7", "role": "http://bioviepharma.com/role/BackgroundInformation", "shortName": "Background Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Liquidity and Going Concern", "menuCat": "Notes", "order": "8", "role": "http://bioviepharma.com/role/LiquidityAndGoingConcern", "shortName": "Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://bioviepharma.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20230630_10k.htm", "contextRef": "From2022-07-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "bivi_AccretionOfLoanPremium": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accretion of loan premium" } } }, "localname": "AccretionOfLoanPremium", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_AccretionOfLoanPremiums": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccretionOfLoanPremiums", "verboseLabel": "Plus accretion of loan premium" } } }, "localname": "AccretionOfLoanPremiums", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_AccretionsOfLoanPremium": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AccretionsOfLoanPremium", "verboseLabel": "Accretion of loan premium" } } }, "localname": "AccretionsOfLoanPremium", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccumulatedDeficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_AcuitasGroupHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acuitas Group Holdings L L C [Member]" } } }, "localname": "AcuitasGroupHoldingsLLCMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_AgentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agent [Member]" } } }, "localname": "AgentMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_AggregateIntrinsicValueOptionsCanceled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Options Canceled" } } }, "localname": "AggregateIntrinsicValueOptionsCanceled", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "bivi_AggregateIntrinsicValueOptionsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Options Exercised" } } }, "localname": "AggregateIntrinsicValueOptionsExercised", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "bivi_AggregateIntrinsicValueOptionsExpired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Options Expired" } } }, "localname": "AggregateIntrinsicValueOptionsExpired", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "bivi_AggregateIntrinsicValueOptionsForfeited": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Options Forfeited" } } }, "localname": "AggregateIntrinsicValueOptionsForfeited", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "bivi_AmortizationExpenseNextRollingThreeYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AmortizationExpenseNextRollingThreeYears", "verboseLabel": "2025" } } }, "localname": "AmortizationExpenseNextRollingThreeYears", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "bivi_AmortizationExpenseNextRollingTwoYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AmortizationExpenseNextRollingTwoYears", "verboseLabel": "2024" } } }, "localname": "AmortizationExpenseNextRollingTwoYears", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "bivi_AmortizationExpenseTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AmortizationExpenseTotal", "verboseLabel": "Total" } } }, "localname": "AmortizationExpenseTotal", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "bivi_AmortizedCostBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortized Cost Basis" } } }, "localname": "AmortizedCostBasis", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "bivi_AvenueWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Avenue Warrants [Member]" } } }, "localname": "AvenueWarrantsMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_CashlessExerciseOfOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cashless exercise of options" } } }, "localname": "CashlessExerciseOfOptions", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bivi_CashlessExerciseOfOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cashless exercise of options, shares" } } }, "localname": "CashlessExerciseOfOptionsShares", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "bivi_CashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants" } } }, "localname": "CashlessExerciseOfWarrants", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bivi_CashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants, shares" } } }, "localname": "CashlessExerciseOfWarrantsShares", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "bivi_ChangeInOperatingLeaseRightofuseAssets": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in operating lease right-of-use assets" } } }, "localname": "ChangeInOperatingLeaseRightofuseAssets", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk in the Financial Service Industry" } } }, "localname": "ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bivi_CurrentPortionOfNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "CurrentPortionOfNotesPayable", "verboseLabel": "Notes Payable" } } }, "localname": "CurrentPortionOfNotesPayable", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_DebtFinancingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "DebtFinancingCosts", "verboseLabel": "Less debt financing costs" } } }, "localname": "DebtFinancingCosts", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability Conversion Option On Convertible Debenture [Member]" } } }, "localname": "DerivativeLiabilityConversionOptionOnConvertibleDebentureMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_DerivativeLiabilityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability Warrants [Member]" } } }, "localname": "DerivativeLiabilityWarrantsMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_DirectFinancingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Direct financing cost" } } }, "localname": "DirectFinancingCost", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_DisclosureEmployeeBenefitPlanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Plan" } } }, "localname": "DisclosureEmployeeBenefitPlanAbstract", "nsuri": "http://bioviepharma.com/20230630", "xbrltype": "stringItemType" }, "bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableForSaleAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments In U.s. Treasury Bills Available For Sale" } } }, "localname": "DisclosureInvestmentsInU.s.TreasuryBillsAvailableForSaleAbstract", "nsuri": "http://bioviepharma.com/20230630", "xbrltype": "stringItemType" }, "bivi_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://bioviepharma.com/20230630", "xbrltype": "stringItemType" }, "bivi_EmployeeBenefitPlanTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EmployeeBenefitPlanTextBlock", "verboseLabel": "Employee Benefit Plan" } } }, "localname": "EmployeeBenefitPlanTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "bivi_ExecutiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Executive [Member]" } } }, "localname": "ExecutiveMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_ExpirationsDates": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expirations dates" } } }, "localname": "ExpirationsDates", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "bivi_FairValueOfEmbeddedConversionOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of embedded conversion option" } } }, "localname": "FairValueOfEmbeddedConversionOption", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_FourDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Four Directors [Member]" } } }, "localname": "FourDirectorsMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_GrossUnrealizedGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross Unrealized Gain" } } }, "localname": "GrossUnrealizedGain", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "bivi_GrossUnrealizedLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross Unrealized loss" } } }, "localname": "GrossUnrealizedLoss", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "bivi_InterestExpenseFromConvertibleDebenture": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "InterestExpenseFromConvertibleDebenture", "negatedLabel": "Accretion of unearned loan discount" } } }, "localname": "InterestExpenseFromConvertibleDebenture", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_InvestmentsInU.s.TreasuryBills": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Investments in U.S. Treasury Bills" } } }, "localname": "InvestmentsInU.s.TreasuryBills", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments in U.S. Treasury Bills available for sale" } } }, "localname": "InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSale" ], "xbrltype": "textBlockItemType" }, "bivi_InvestmentsUSTreasuryBillsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "InvestmentsUSTreasuryBillsPolicyTextBlock", "verboseLabel": "Investments in U.S. Treasury Bills" } } }, "localname": "InvestmentsUSTreasuryBillsPolicyTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bivi_LoanAccretionPremiumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Accretion Premium [Member]" } } }, "localname": "LoanAccretionPremiumMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "bivi_LongTermAccretionOfLoanPremiums": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Plus accretion of loan premium" } } }, "localname": "LongTermAccretionOfLoanPremiums", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Less unearned discount" } } }, "localname": "LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current portion of Notes Payable, net of financing costs, unearned premiums and discount" } } }, "localname": "LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_LongtermDebtFinancingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Less debt financing costs" } } }, "localname": "LongtermDebtFinancingCosts", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_N2019OmnibusIncentiveEquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "N 2019 Omnibus Incentive Equity Plan [Member]" } } }, "localname": "N2019OmnibusIncentiveEquityPlanMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of common stock \u2013 Related Party" } } }, "localname": "NetProceedsFromIssuanceOfCommonStockRelatedParty", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_NewEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New Employee [Member]" } } }, "localname": "NewEmployeeMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_NotesPayableNetOfCurrentPortionFinancingCostsUnearnedPremiumsAndDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Notes Payable, net of the current portion financing costs, unearned premiums and discount" } } }, "localname": "NotesPayableNetOfCurrentPortionFinancingCostsUnearnedPremiumsAndDiscount", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_NotesPayableNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current portion of Notes Payable" } } }, "localname": "NotesPayableNoncurrent", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "bivi_NumberOfStockPurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Number of stock purchased" } } }, "localname": "NumberOfStockPurchased", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_OperatingLeaseLiabilitiesNetOfCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OperatingLeaseLiabilitiesNetOfCurrentPortion", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilitiesNetOfCurrentPortion", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "bivi_OptionsCanceled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options Canceled" } } }, "localname": "OptionsCanceled", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "sharesItemType" }, "bivi_OtherAssetsnoncurrentPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, non-current" } } }, "localname": "OtherAssetsnoncurrentPolicyTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bivi_PrepaidAndOtherAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid and other Assets" } } }, "localname": "PrepaidAndOtherAssetsPolicyTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bivi_PresentValueOfFutureMinimumLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Present value of future minimum lease payments" } } }, "localname": "PresentValueOfFutureMinimumLeasePayments", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "bivi_PresidentAndCEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "President And C E O [Member]" } } }, "localname": "PresidentAndCEOMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOf94160RelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, net of costs of\u00a0\u00a0$94,160 \u2013 Related Party" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfCostsOf94160RelatedParty", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfrelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock related party, shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfCostsOfrelatedPartyShares", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "bivi_PurchasesOfU.s.TreasuryBills": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PurchasesOfU.s.TreasuryBills", "negatedLabel": "Purchases of U.S. Treasury Bills" } } }, "localname": "PurchasesOfU.s.TreasuryBills", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_RsuGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rsu granted" } } }, "localname": "RsuGranted", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bivi_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales Agreement [Member]" } } }, "localname": "SalesAgreementMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future estimated minimum lease payments under non-cancelable operating leases" } } }, "localname": "ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bivi_ScheduleOfNoncashFinancingAndInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:" } } }, "localname": "ScheduleOfNoncashFinancingAndInvestingActivitiesAbstract", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of U.S. treasury bills held" } } }, "localname": "ScheduleOfUSTreasuryBillsHeldTableTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleTables" ], "xbrltype": "textBlockItemType" }, "bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted average remaining lease term and discount rate" } } }, "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bivi_ScheduleofFutureAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Estimated future amortization expense and accretion of premium" } } }, "localname": "ScheduleofFutureAmortizationExpenseTableTextBlock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised", "verboseLabel": "Rsu granted, grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpired", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, at the end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease1", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "perShareItemType" }, "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Term, Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "durationItemType" }, "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Contractual Term, Granted (in Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Remaining Average Contractual Term, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "durationItemType" }, "bivi_SharesIssuedOverVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued over the vesting period" } } }, "localname": "SharesIssuedOverVestingPeriod", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bivi_StockBasedCompensationExpenseStockIssued": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock based compensation expense \u2013 stock issued" } } }, "localname": "StockBasedCompensationExpenseStockIssued", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_StockBasedCompensationRestrictedStock": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock based compensation \u2013 restricted stock units" } } }, "localname": "StockBasedCompensationRestrictedStock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_StockOption10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 10 [Member]" } } }, "localname": "StockOption10Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption11Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 11 [Member]" } } }, "localname": "StockOption11Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption12Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 12 [Member]" } } }, "localname": "StockOption12Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption13Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 13 [Member]" } } }, "localname": "StockOption13Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption14Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 14 [Member]" } } }, "localname": "StockOption14Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption15Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 15 [Member]" } } }, "localname": "StockOption15Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 16 [Member]" } } }, "localname": "StockOption16Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption17Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 17 [Member]" } } }, "localname": "StockOption17Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption18Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 18 [Member]" } } }, "localname": "StockOption18Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 19 [Member]" } } }, "localname": "StockOption19Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 1 [Member]" } } }, "localname": "StockOption1Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption20Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 20 [Member]" } } }, "localname": "StockOption20Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption21Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 21 [Member]" } } }, "localname": "StockOption21Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption22Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 22 [Member]" } } }, "localname": "StockOption22Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 23 [Member]" } } }, "localname": "StockOption23Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 2 [Member]" } } }, "localname": "StockOption2Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 3 [Member]" } } }, "localname": "StockOption3Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 4 [Member]" } } }, "localname": "StockOption4Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 5 [Member]" } } }, "localname": "StockOption5Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 6 [Member]" } } }, "localname": "StockOption6Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 7 [Member]" } } }, "localname": "StockOption7Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 8 [Member]" } } }, "localname": "StockOption8Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOption9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 9 [Member]" } } }, "localname": "StockOption9Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "domainItemType" }, "bivi_StockOptionAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option And Warrants [Member]" } } }, "localname": "StockOptionAndWarrantsMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_StockbasedCompensationIssuanceOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock-based compensation \u2013 issuance of common stock" } } }, "localname": "StockbasedCompensationIssuanceOfCommonStock", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bivi_StockbasedCompensationIssuanceOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based compensation - issuance of common stock, shares" } } }, "localname": "StockbasedCompensationIssuanceOfCommonStockShares", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "bivi_StockholderEquities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "localname": "StockholderEquities", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_ThreeDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Directors [Member]" } } }, "localname": "ThreeDirectorsMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_TotalCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total compensation cost" } } }, "localname": "TotalCompensationCost", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_TotalOtherExpenseIncome": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "TotalOtherExpenseIncome", "totalLabel": "TOTAL OTHER EXPENSE (INCOME), NET" } } }, "localname": "TotalOtherExpenseIncome", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bivi_TreasuryStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Treasury Stocks [Member]" } } }, "localname": "TreasuryStocksMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "bivi_USTreasuryBillSecurities1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U S Treasury Bill Securities 1 [Member]" } } }, "localname": "USTreasuryBillSecurities1Member", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "domainItemType" }, "bivi_UnearnedDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unearned discount" } } }, "localname": "UnearnedDiscount", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bivi_UnearnedDiscountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unearned Discount [Member]" } } }, "localname": "UnearnedDiscountMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "bivi_UnearnedPremiumAndDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unearned premium and discount" } } }, "localname": "UnearnedPremiumAndDiscount", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "bivi_UnearnedPremiumAnddiscountCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unearned premium and discount current" } } }, "localname": "UnearnedPremiumAnddiscountCurrent", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "bivi_UnrealizedGainOnAvailableforsaleSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain on available-for-sale securities" } } }, "localname": "UnrealizedGainOnAvailableforsaleSecurities", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bivi_UnrealizedGainOnInvestmentsForAvailableforsale": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain on investments for available-for-sale" } } }, "localname": "UnrealizedGainOnInvestmentsForAvailableforsale", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bivi_UnrealizedGainOnU.s.TreasuryBill": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain on U.S. Treasury Bills" } } }, "localname": "UnrealizedGainOnU.s.TreasuryBill", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_WarrantLiabilities": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant liabilities" } } }, "localname": "WarrantLiabilities", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "bivi_WeightedAverageExercisePriceOptionsCanceled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Options Canceled" } } }, "localname": "WeightedAverageExercisePriceOptionsCanceled", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "perShareItemType" }, "bivi_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://bioviepharma.com/20230630", "presentation": [ "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r650", "r652", "r653" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r650", "r652", "r653" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r650", "r652", "r653" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r650", "r652", "r653" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFinStmtErrorCorrectionFlag": { "auth_ref": [ "r650", "r652", "r653", "r655" ], "lang": { "en-us": { "role": { "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.", "label": "Document Financial Statement Error Correction [Flag]" } } }, "localname": "DocumentFinStmtErrorCorrectionFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r650", "r652", "r653" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r649" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r165", "r166", "r228", "r255", "r380", "r604", "r606" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r278", "r389", "r423", "r454", "r455", "r518", "r537", "r542", "r543", "r582", "r601", "r602", "r610", "r617", "r622", "r627", "r680", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r278", "r389", "r423", "r454", "r455", "r518", "r537", "r542", "r543", "r582", "r601", "r602", "r610", "r617", "r622", "r627", "r680", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r211", "r212", "r213", "r214", "r269", "r278", "r303", "r304", "r305", "r388", "r389", "r423", "r454", "r455", "r518", "r537", "r542", "r543", "r582", "r601", "r602", "r610", "r617", "r622", "r627", "r630", "r676", "r680", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r269", "r278", "r303", "r304", "r305", "r388", "r389", "r423", "r454", "r455", "r518", "r537", "r542", "r543", "r582", "r601", "r602", "r610", "r617", "r622", "r627", "r630", "r676", "r680", "r722", "r723", "r724", "r725", "r726" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r165", "r166", "r228", "r255", "r380", "r605", "r606" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r672", "r717" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r17", "r626" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/OtherLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r147", "r148", "r354", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r31", "r93", "r137", "r415", "r428", "r429" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive income", "verboseLabel": "Total Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r147", "r148", "r354", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r3", "r8", "r31", "r339", "r342", "r374", "r424", "r425", "r662", "r663", "r664", "r669", "r670", "r671" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r86" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r307", "r308", "r309", "r443", "r669", "r670", "r671", "r714", "r734" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r7", "r72", "r98", "r246" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of financing costs" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r95", "r246", "r363", "r666" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r7", "r46", "r50" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization", "terseLabel": "Amortization expenses", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfCashFlows", "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r118", "r136", "r163", "r193", "r196", "r198", "r201", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r332", "r336", "r353", "r411", "r476", "r626", "r638", "r678", "r679", "r719" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r130", "r138", "r163", "r201", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r332", "r336", "r353", "r626", "r678", "r679", "r719" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r35", "r132", "r603" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r35", "r99", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r2", "r99" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r661", "r729" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalent" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r79", "r412", "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r106", "r209", "r210", "r600", "r677" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r628", "r629", "r630", "r632", "r633", "r634", "r635", "r669", "r670", "r714", "r730", "r734" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r85", "r464" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued", "verboseLabel": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical", "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r85", "r464", "r482", "r734", "r735" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r85", "r414", "r626" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2023 and June 30, 2022, respectively; 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023 and 24,984,083\u00a0issued and outstanding at June 30, 2022;" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets (liabilities):" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r32", "r143", "r145", "r152", "r407", "r421" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r39", "r40", "r70", "r71", "r200", "r599" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r39", "r40", "r70", "r71", "r200", "r430", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r107", "r161", "r224", "r230", "r231", "r232", "r233", "r234", "r235", "r240", "r247", "r248", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r23", "r73", "r243" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r167", "r225", "r226", "r227", "r228", "r229", "r231", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r249", "r364", "r612", "r613", "r614", "r615", "r616", "r667" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "auth_ref": [ "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to interest.", "label": "Interest payment" } } }, "localname": "DebtInstrumentPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r24", "r51", "r52", "r72", "r73", "r75", "r80", "r109", "r110", "r167", "r225", "r226", "r227", "r228", "r229", "r231", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r249", "r364", "r612", "r613", "r614", "r615", "r616", "r667" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedPremium": { "auth_ref": [ "r72", "r75", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt premium.", "label": "Unamortized premium recognized" } } }, "localname": "DebtInstrumentUnamortizedPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unearned discounts (other than cash or quantity discounts and the like), finance charges, and interest included in the face amount of receivables, that are shown as a deduction from the related receivables. For example, 1) finance charges booked as a receivable when a loan is made and recognized as income at a later date; and 2) interest charges deducted from the face loan amount, resulting in a discounted amount actually advanced to the borrower (wherein the receivable includes the amount actually advanced to the borrower and the as yet unearned interest income).", "label": "Deferred Discounts, Finance Charges and Interest Included in Receivables", "negatedLabel": "Less unearned discount" } } }, "localname": "DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r61", "r711" ], "calculation": { "http://bioviepharma.com/role/IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Tax loss carryforward" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r61", "r711" ], "calculation": { "http://bioviepharma.com/role/IncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "R&D capitalized" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r710" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r710" ], "calculation": { "http://bioviepharma.com/role/IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r61", "r711" ], "calculation": { "http://bioviepharma.com/role/IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r320" ], "calculation": { "http://bioviepharma.com/role/IncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r268", "r270", "r277", "r618", "r619", "r620", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "verboseLabel": "Employee Benefit Plan" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r452", "r455", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r495", "r496", "r497", "r498", "r501", "r502", "r503", "r504", "r563", "r564", "r567", "r569", "r628", "r630" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r713" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r62", "r64", "r65", "r66", "r452", "r455", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r495", "r496", "r497", "r498", "r501", "r502", "r503", "r504", "r563", "r564", "r567", "r569", "r606", "r628", "r630" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r139", "r140", "r352", "r445", "r446", "r447", "r449", "r450", "r451", "r452", "r454", "r455", "r477", "r479", "r480", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r606", "r731" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Total derivatives", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r153", "r173", "r174", "r175", "r176", "r177", "r181", "r184", "r187", "r188", "r189", "r191", "r346", "r347", "r408", "r422", "r607" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "- Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r153", "r173", "r174", "r175", "r176", "r177", "r184", "r187", "r188", "r189", "r191", "r346", "r347", "r408", "r422", "r607" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "- Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r164", "r315", "r327" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Income tax expense at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r708", "r712" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r708", "r712" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r63" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded derivative liability" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r9", "r128", "r147", "r148", "r149", "r168", "r169", "r170", "r172", "r178", "r180", "r192", "r202", "r203", "r267", "r307", "r308", "r309", "r324", "r325", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r354", "r356", "r357", "r358", "r359", "r360", "r374", "r424", "r425", "r426", "r443", "r507" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r1", "r7" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r15", "r67", "r69", "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r238", "r270", "r271", "r272", "r273", "r274", "r275", "r350", "r385", "r386", "r387", "r613", "r614", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r238", "r270", "r275", "r350", "r385", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r238", "r270", "r275", "r350", "r386", "r613", "r614", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r238", "r270", "r271", "r272", "r273", "r274", "r275", "r350", "r387", "r613", "r614", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r10", "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair value, liabilities measured on recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurement of assets and liabilities" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in in fair value of level 3 liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Additions to level 3 liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Transfer in and/or out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "verboseLabel": "Total" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r238", "r270", "r271", "r272", "r273", "r274", "r275", "r385", "r386", "r387", "r613", "r614", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Financing Receivable [Member]" } } }, "localname": "FinanceReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r134", "r208" ], "calculation": { "http://bioviepharma.com/role/IntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r104", "r392" ], "calculation": { "http://bioviepharma.com/role/IntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intellectual Property" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r104", "r391" ], "calculation": { "http://bioviepharma.com/role/IntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intellectual Property, Net", "totalLabel": "Intellectual Property, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails", "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r7", "r121", "r495", "r496", "r497", "r498" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "bivi_TotalOtherExpenseIncome", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain (Loss) on Sale of Derivatives", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r133", "r205", "r405", "r611", "r626", "r674", "r675" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill impairments" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r204", "r206", "r611" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r105" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r96", "r149" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r164", "r312", "r316", "r317", "r322", "r326", "r328", "r329", "r330", "r438" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r709" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Interest or penalty" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r146", "r313", "r314", "r317", "r318", "r321", "r323", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r6" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r660", "r665" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r6" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r6" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaids and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r45", "r48" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r74", "r122", "r150", "r194", "r362", "r492", "r636", "r733" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "bivi_TotalOtherExpenseIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r98", "r244", "r251", "r615", "r616" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "bivi_TotalOtherExpenseIncome", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r155", "r158", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedUnrecognizedUnrealizedDepreciation": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the excess of the cost (face amount, notional amount) of an investment (security, contract) over its fair value which deficiency has not been recognized in earnings of the entity.", "label": "Fair Value" } } }, "localname": "InvestmentOwnedUnrecognizedUnrealizedDepreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r446", "r448", "r449", "r450", "r453", "r515", "r524", "r538", "r546", "r559", "r571", "r572", "r588", "r592", "r593", "r594", "r595", "r630" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r446", "r448", "r449", "r450", "r453", "r515", "r524", "r538", "r546", "r559", "r571", "r572", "r588", "r592", "r593", "r594", "r595", "r630" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of balance sheet information related to leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ending June 30, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r163", "r201", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r333", "r336", "r337", "r353", "r462", "r608", "r638", "r678", "r719", "r720" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r90", "r119", "r417", "r626", "r668", "r673", "r715" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u0092 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u0092 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r131", "r163", "r201", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r333", "r336", "r337", "r353", "r626", "r678", "r719", "r720" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r24" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable, net of current portion, financing cost, unearned premium and\u00a0\u00a0discount of $227,268 at June 30, 2023 and $2,861,314 at June 30, 2022" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r157" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r157" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r100", "r101" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r94", "r101", "r120", "r129", "r141", "r144", "r149", "r163", "r171", "r173", "r174", "r175", "r176", "r179", "r180", "r185", "r193", "r195", "r197", "r199", "r201", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r347", "r353", "r419", "r484", "r505", "r506", "r609", "r636", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r154", "r173", "r174", "r175", "r176", "r181", "r182", "r186", "r189", "r193", "r195", "r197", "r199", "r609" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "NET LOSS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of Note payable, net of financing cost, unearned premium and\u00a0\u00a0discount of $894,926 at June 30, 2023" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r193", "r195", "r197", "r199", "r609" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r369", "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r367" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liabilities", "negatedLabel": "Less current portion of operating lease liabilities", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/LeasesDetails", "http://bioviepharma.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r367" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r366" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "verboseLabel": "Operating lease, right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r372", "r625" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r371", "r625" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term (Years) Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LeasesDetails2" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net Operating Loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r82", "r116", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Background Information" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BackgroundInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r135" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets, non-current" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r9", "r16", "r142", "r145", "r151", "r354", "r355", "r360", "r406", "r420", "r662", "r663" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE (INCOME):" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r78", "r410", "r458", "r459", "r638", "r732" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/OtherLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r20", "r626" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Current portion of other liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/OtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other liabilities, net of current portion" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Commission and expenses" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Issuance cost" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r84", "r253" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r84", "r464" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r84", "r253" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r84", "r464", "r482", "r734", "r735" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r84", "r413", "r626" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaids and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r4" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r33" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from note payable net of financing costs" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r4", "r14" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r129", "r141", "r144", "r156", "r163", "r171", "r179", "r180", "r193", "r195", "r197", "r199", "r201", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r331", "r334", "r335", "r347", "r353", "r409", "r418", "r442", "r484", "r505", "r506", "r609", "r623", "r624", "r637", "r664", "r678" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bioviepharma.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows", "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r276", "r378", "r379", "r457", "r458", "r459", "r460", "r461", "r481", "r483", "r514" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r487", "r488", "r491" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r276", "r378", "r379", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r457", "r458", "r459", "r460", "r461", "r481", "r483", "r514", "r718" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r375", "r376", "r377", "r379", "r381", "r439", "r440", "r441", "r489", "r490", "r491", "r511", "r513" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r81", "r311", "r727" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r87", "r111", "r416", "r427", "r429", "r437", "r465", "r626" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r168", "r169", "r170", "r172", "r178", "r180", "r202", "r203", "r307", "r308", "r309", "r324", "r325", "r338", "r340", "r341", "r343", "r345", "r424", "r426", "r443", "r734" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r370", "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right of use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Number of stock sold", "verboseLabel": "Value of common stock sold" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Number of common stock sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Dilutive securities were excluded from the computation of diluted loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Summary of warrants activity" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of note payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of derivative liabilities at fair value" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r47", "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [ "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r573", "r574", "r575", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investments owned by investment company.", "label": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r76", "r77", "r487", "r488", "r491" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r12", "r13", "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of summarizes the activity relating to the Company\u2019s stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of assumptions used" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of summary of stock options outstanding and exercisable" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).", "label": "Schedule of vesting of restricted common stock" } } }, "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of future amortization expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r97" ], "calculation": { "http://bioviepharma.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r6" ], "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation expense \u2013 stock options", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Warrant Outstanding, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "periodEndLabel": "Weighted Average Exercise Price, at the end of period", "periodStartLabel": "Weighted Average Exercise Price, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares Unvested at ending", "periodStartLabel": "Number of Shares Unvested at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3", "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share at ending", "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Life, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares Unvested, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Grant Date Fair Value Per Share, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk Free Interest Rate", "verboseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options Granted", "terseLabel": "Options Grants", "verboseLabel": "Number of Shares Unvested, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails3", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Outstanding", "periodEndLabel": "Options outstanding at ending", "periodStartLabel": "Options outstanding at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Options outstanding at ending", "periodStartLabel": "Weighted average exercise price, Options outstanding at beginning", "verboseLabel": "Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options Exercisable", "verboseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Exercise Price, Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails3", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price, Options Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "negatedLabel": "Weighted Average Exercise Price, Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Options Granted", "terseLabel": "Weighted Average Exercise Price, Options Grants", "verboseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails3", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r682" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Awarded Vested rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Aggregate Intrinsic Value, Outstanding at beginning of period", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at end of period", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at beginning of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Aggregate Intrinsic Value, Options Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term", "verboseLabel": "Expected life of options (In years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate Intrinsic Value, Options Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Term, Options outstanding at beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Remaining Contractual Term, Options Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r9", "r28", "r128", "r147", "r148", "r149", "r168", "r169", "r170", "r172", "r178", "r180", "r192", "r202", "r203", "r267", "r307", "r308", "r309", "r324", "r325", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r354", "r356", "r357", "r358", "r359", "r360", "r374", "r424", "r425", "r426", "r443", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r168", "r169", "r170", "r192", "r390", "r433", "r444", "r456", "r457", "r458", "r459", "r460", "r461", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r483", "r485", "r486", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r507", "r631" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r168", "r169", "r170", "r192", "r390", "r433", "r444", "r456", "r457", "r458", "r459", "r460", "r461", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r483", "r485", "r486", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r507", "r631" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Shares issued to employees" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock issued during period for service" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r84", "r85", "r111", "r435", "r507", "r596" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Proceeds from issuance of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued for stock option" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r9", "r84", "r85", "r111" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Rsu awarded" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r9", "r111" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock-based compensation - restricted stock units, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r84", "r85", "r111", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Proceeds from exercise of options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r84", "r85", "r111", "r443", "r507", "r596", "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Proceeds from issuance of common stock, net costs of $2,008,898", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r9", "r84", "r85", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock-based compensation \u2013 restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r59", "r84", "r85", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock option-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r9", "r28", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Proceeds from exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r9", "r84", "r85", "r111", "r436", "r507", "r597" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock option to purchase" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r85", "r88", "r89", "r103", "r466", "r482", "r508", "r509", "r626", "r638", "r668", "r673", "r715", "r734" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u0092 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u0092 EQUITY :" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r108", "r162", "r252", "r254", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r344", "r510", "r512", "r598" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity Transactions" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r361", "r383" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r361", "r383" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r361", "r383" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r361", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r361", "r383" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r382", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Liquidity and Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/LiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r27", "r53", "r54" ], "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r41", "r42", "r43", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r628", "r629", "r632", "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails4", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r183", "r189" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "- Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON\u00a0\u00a0SHARES OUTSTANDING" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r181", "r189" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "- Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//350-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r641": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r642": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r643": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r644": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r645": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r646": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r647": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r648": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r649": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r651": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r652": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r653": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r654": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r655": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r656": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r657": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r658": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r659": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }